VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ELCC 2019 | Second-generation ALK inhibitors in ALK-positive NSCLC

Antonio Passaro, MD, PhD, of European Institute of Oncology IRCCS, Milan, Italy, talks about the survival benefits brought by second-generation ALK inhibitors in patients with ALK-positive non-small cell lung cancer (NSCLC). This video was recorded at the European Lung Cancer Congress (ELCC) 2019, held in Geneva, Switzerland.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter